Eli Lilly Dramatically Escalates Efforts to Restrict Access to 340B Pricing

In Federal, Pharma Industry, RegulatorySeptember 1, 2020120 Views

Note from the Publisher and CEO Ted Slafsky: Bronwyn Mixter is filling in for Tom Mirga this week. If you have story ideas or tips, feel free to reach her at bronwyn.mixter@340breport.com or 703-403-5926. We’re pleased to include in today’s issue sponsored content from 340B Report sponsor Trellis Rx who will be hosting a webinar September 9th on enhancing patient care in the infectious disease setting with 340B health system specialty pharmacy services. See details below.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

Eli Lilly Dramatically Escalates Efforts to Restrict Access to 340B Pricing

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga

Eli Lilly Dramatically Escalates Efforts to Restrict Access to 340B Pricing

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga

Site Footer